Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer

Abstract Background Entinostat is an oral inhibitor of class I histone deacetylases intended for endocrine therapy-resistant patients with hormone receptor-positive (HR+) advanced or metastatic breast cancer (BC). We examined the safety, efficacy, and pharmacokinetics of entinostat monotherapy and c...

Full description

Bibliographic Details
Main Authors: Norikazu Masuda, Kenji Tamura, Hiroyuki Yasojima, Akihiko Shimomura, Masataka Sawaki, Min-Jung Lee, Akira Yuno, Jane Trepel, Ryoko Kimura, Yozo Nishimura, Shigehira Saji, Hiroji Iwata
Format: Article
Language:English
Published: BMC 2021-11-01
Series:BMC Cancer
Subjects:
Acetylation
Aromatase inhibitors
Drug resistance
Epigenomics
Histone deacetylases
Online Access:https://doi.org/10.1186/s12885-021-08973-4

Internet

https://doi.org/10.1186/s12885-021-08973-4

Similar Items